589 Views

Instructional Course

Instructional Course - Available with the Platinum and Silver packages or Individual Course Ticket

046IC - Integrating Care for Oncology Patients: Establishing a Multidisciplinary Oncology Clinic with Advanced Therapeutics

Saturday, May 14, 2022

4:00 PM – 6:00 PM

Location: Room 208

Instructional Course Director(s)

Kelly L. Stratton, MD

Associate Professor
Department of Urology, Stephenson Cancer Center, University of Oklahoma

Instructional Course Faculty(s)

Alicia Morgans, MD, MPH

Faculty in Medicine
Harvard Medical School, Dana-Farber Cancer Institute
Kelvin A. Moses, MD, PHD

Associate Professor
Vanderbilt University Medical Center
Brian Matthew Shuch, MD

Associate Professor of Urology, Director of the Kidney Cancer Program
Urology

Learning Objectives:

Describe the components of a multidisciplinary urologic cancer clinic and identify the best structure for the practice.
Deliver advanced therapeutics based on current and emerging best evidence including immunotherapy in urologic oncology patients.
Identify opportunities for shared care and team-based approaches of patients with urologic cancers including advanced prostate, bladder, and kidney cancer.
Discuss advances in genomic testing and personalized medicine for urologic cancers.
Differentiate between new therapeutics that expand the treatment options for patients with urologic cancers and alter the definitions of cancer treatment.

This course will provide the framework to create a multidisciplinary clinic for the treatment of urologic malignancies, with representation of urologists, medical oncologists and additional specialists working together in a team-based approach. The course will focus on integration of advanced therapeutics including immune-based therapy where applicable in a multidisciplinary setting. Participants will have a better understanding of the best timing for referrals to medical oncology with specific examples including hormone sensitive metastatic prostate cancer, neoadjuvant chemotherapy for muscle invasive bladder cancer, role of immunotherapy in bladder and kidney cancer. The integration of genomic tumor characterization and personalized medicine into surgical planning, tumor biopsies, and chemo-immunotherapy selection will be discussed. An emphasis will be placed on the upcoming expansion of checkpoint inhibitors in urologic malignancies and the changing definitions of disease progression.